Please use this identifier to cite or link to this item: http://hdl.handle.net/10553/124196
Title: Effects of ozone therapy on anxiety and depression in patients with refractory symptoms of severe diseases: a pilot study
Authors: Clavo Varas,Bernardino 
Cánovas-Molina, Angeles
Díaz-Garrido, Juan A.
Cañas, Silvia
Ramallo Fariña, Yolanda 
Laffite, Horus
Federico, Mario
Rodríguez Abreu, Delvys 
Galván, Saray
García-Lourve, Carla
González-Beltrán, Damián
Caramés Álvarez,Miguel Angel 
Hernández-Fleta, Jose L.
Serrano-Aguilar, Pedro
Rodríguez Esparragón,Francisco Javier 
UNESCO Clasification: 32 Ciencias médicas
320101 Oncología
61 Psicología
Keywords: Advanced Diseases
Anxiety And Depression
Cancer Survivors
Chemotherapy-Induced Neuropathy
Chemotherapy-Induced Side Effects, et al
Issue Date: 2023
Journal: Frontiers in Psychology 
Abstract: Background: Patients with refractory symptoms of severe diseases frequently experience anxiety, depression, and an altered health-related quality of life (HRQOL). Some publications have described the beneficial effect of ozone therapy on several symptoms of this kind of patient. The aim of this study was to preliminarily evaluate, in patients treated because of refractory symptoms of cancer treatment and advanced nononcologic diseases, if ozone therapy has an additional impact on self-reported anxiety and depression. Methods: Before and after ozone treatment, we assessed (i) anxiety and depression according to the Hospital Anxiety and Depression Scale (HADS); (ii) the HRQOL (according to the EQ-5D-5L questionnaire), which includes a dimension on anxiety and depression and a visual analog scale (VAS) measuring self-perceived general health. Results: Before ozone therapy, 56% of patients were on anxiolytic and/or antidepressant treatment. Before and after ozone therapy, the anxiety and depression HADS subscales (i) significantly correlated with the anxiety/depression dimension of the EQ-5D-5L questionnaire and (ii) inversely correlated with the health status as measured by the VAS. After ozone therapy, we found a significant improvement in anxiety and depression measured by both the (i) HADS subscales and (ii) EQ-5D-5L questionnaire. Conclusion: The addition of ozone therapy for patients with refractory symptoms of cancer treatment and advanced chronic nononcologic diseases can decrease anxiety and depression severity levels. Additional, more focused studies are ongoing to provide the needed explanatory information for this finding.
URI: http://hdl.handle.net/10553/124196
DOI: 10.3389/fpsyg.2023.1176204
Source: Frontiers in Psychology[EISSN 1664-1078],v. 14:1176204, (Agosto 2023)
Appears in Collections:Artículos
Adobe PDF (839,6 kB)
Show full item record

Google ScholarTM

Check

Altmetric


Share



Export metadata



Items in accedaCRIS are protected by copyright, with all rights reserved, unless otherwise indicated.